Clinical trial · people
Pramlintide pump infusion: HbA1c fell 0.35% in 16-week pilot
Checked against the paper Clinical trialPublished by PepVault
The takeaway
Early, small-scale evidence that pump-delivered pramlintide in type 1 diabetes lowered fasting glucose and mealtime insulin needs, with mild low blood sugar after meals in everyone.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 11
- Published
- 2009
- Journal
- Endocr Pract
What they tested
The team wanted to see whether giving pramlintide through a pump, as a steady background dose plus extra doses before meals, works and is safe in people with type 1 diabetes.
How the study was done
An open-label, single-arm pilot trial (everyone got the drug, everyone knew it, and there was no comparison group) in 11 adults with long-standing type 1 diabetes who already used insulin pumps, run for 16 weeks. Insulin doses were lowered by 10% when pramlintide started and then adjusted to avoid low blood sugar.

Model. Individual results vary.
What they found
After 16 weeks, average HbA1c (a 3-month average of blood sugar) went from 8.20% to 7.85%, a drop of 0.35%. Fasting glucose fell from 198.2 to 135.8 mg/dL, and weight was down 0.5 kg at week 12. The daily mealtime insulin dose fell 20%, while background insulin stayed the same at 27.7 U. Every patient had mild low blood sugar after meals but none had severe episodes, and 3 of the 11 had mild nausea early on.
What it doesn’t show
This was a very small, short pilot with no control group, so the changes can't be firmly credited to pramlintide. The authors called for larger studies.
The paper
Huffman et al. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract. 2009.
The compound
More studies on Pramlintide
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinMeta-analysis · people · 2003
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose groupRandomized trial · people · 2023
- Pramlintide: weight loss maintained over 12 months in obesityRandomized trial · people · 2008
- Pramlintide: 3.7% placebo-corrected weight loss at 16 weeksRandomized trial · people · 2007
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.